LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 37

Search options

  1. Article: Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer.

    Vokes, Natalie I / Pan, Kelsey / Le, Xiuning

    Therapeutic advances in medical oncology

    2023  Volume 15, Page(s) 17588359231161409

    Abstract: For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of ... ...

    Abstract For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers.
    Language English
    Publishing date 2023-03-18
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359231161409
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers.

    Vokes, Natalie I / Zhang, Jianjun

    Lung Cancer (Auckland, N.Z.)

    2021  Volume 12, Page(s) 139–149

    Abstract: Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often require ... ...

    Abstract Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often require adjuvant chemotherapy or may in fact be incurable stage IV lesions. Conversely, MLTs that represent distinct primaries have a better prognosis and may be overtreated if inappropriately classified as related secondaries. Historically, pathologic and radiographic criteria were used to distinguish between primary and secondary MLTs; however, the advent of genomic profiling has demonstrated limitations to these historic classification systems. In this review, we discuss the use of molecular profiling to distinguish between primary and secondary lung cancers, with a focus on the insights gleaned from whole exome sequencing (WES) analyses. While WES is not yet feasible in routine clinical practice, WES studies have helped elucidate the clonal relationship between primary and secondary lung cancers and provide important context for the application of targeted sequencing panel-based analyses.
    Language English
    Publishing date 2021-12-02
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2587467-6
    ISSN 1179-2728
    ISSN 1179-2728
    DOI 10.2147/LCTT.S272518
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Resistance in trans-ition.

    Vokes, Natalie I / Jänne, Pasi A

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2017  Volume 12, Issue 11, Page(s) 1608–1610

    MeSH term(s) ErbB Receptors/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics
    Chemical Substances EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2017-10-06
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2017.09.1953
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Giving up surgery.

    Vokes, Natalie I

    Annals of internal medicine

    2012  Volume 157, Issue 11, Page(s) 829–830

    MeSH term(s) Career Choice ; Curriculum ; Education, Medical, Undergraduate ; General Surgery/education ; Humans ; Stress, Psychological ; Students, Medical/psychology
    Language English
    Publishing date 2012-12-04
    Publishing country United States
    Document type Editorial ; Personal Narratives
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/0003-4819-157-11-201212040-00016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.178/2: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Tumor Growth Rate After Nadir Is Associated With Survival in Patients With

    Nishino, Mizuki / Lu, Junwei / Hino, Takuya / Vokes, Natalie I / Jänne, Pasi A / Hatabu, Hiroto / Johnson, Bruce E

    JCO precision oncology

    2022  Volume 5, Page(s) 1603–1610

    Abstract: Purpose: To investigate the association between tumor volume growth rate after the nadir and survival in patients with : Materials and methods: Seventy-one patients with : Results: The median tumor volume for the cohort was 19,842 mm: Conclusion! ...

    Abstract Purpose: To investigate the association between tumor volume growth rate after the nadir and survival in patients with
    Materials and methods: Seventy-one patients with
    Results: The median tumor volume for the cohort was 19,842 mm
    Conclusion: In patients with
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Cohort Studies ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/therapeutic use ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Survival Rate ; Tumor Burden
    Chemical Substances Protein Kinase Inhibitors ; Erlotinib Hydrochloride (DA87705X9K) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2022-01-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.21.00172
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma.

    Liu, David / Vokes, Natalie I / Van Allen, Eliezer M

    Cancer discovery

    2017  Volume 7, Issue 6, Page(s) 555–557

    Abstract: ... Assessing the benefit of routine panel-based genomic sequencing of tumor tissue remains a critical need in clinical oncology. Jordan and coauthors report on 860 patients with metastatic or recurrent lung adenocarcinoma from a single institution with ...

    Abstract <b/> Assessing the benefit of routine panel-based genomic sequencing of tumor tissue remains a critical need in clinical oncology. Jordan and coauthors report on 860 patients with metastatic or recurrent lung adenocarcinoma from a single institution with prospectively sequenced tumors using a targeted gene panel of >300 genes to guide therapy. Their results suggest that early prospective tumor sequencing, including non-standard-of-care predictive biomarkers combined with careful clinical annotation, can guide therapy, improve clinical outcomes, and accelerate the development of biomarkers and drugs.
    MeSH term(s) Adenocarcinoma/genetics ; Adenocarcinoma/therapy ; Adenocarcinoma of Lung ; Biomarkers, Tumor/genetics ; DNA, Neoplasm ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/therapy ; Molecular Targeted Therapy ; Precision Medicine ; Sequence Analysis, DNA
    Chemical Substances Biomarkers, Tumor ; DNA, Neoplasm
    Language English
    Publishing date 2017-05-29
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-17-0355
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Tumor Evolution: A Problem of Histocompatibility.

    Vokes, Natalie I / Van Allen, Eliezer M

    Cell

    2017  Volume 171, Issue 6, Page(s) 1252–1253

    Abstract: In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cell survival. ...

    Abstract In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cell survival.
    MeSH term(s) Alleles ; Antigen Presentation ; Antigens, Neoplasm ; Histocompatibility Antigens Class I/genetics ; Humans ; Lung Neoplasms
    Chemical Substances Antigens, Neoplasm ; Histocompatibility Antigens Class I
    Language English
    Publishing date 2017-12-01
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2017.11.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1167: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 58: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review.

    Al-Tashi, Qasem / Saad, Maliazurina B / Muneer, Amgad / Qureshi, Rizwan / Mirjalili, Seyedali / Sheshadri, Ajay / Le, Xiuning / Vokes, Natalie I / Zhang, Jianjun / Wu, Jia

    International journal of molecular sciences

    2023  Volume 24, Issue 9

    Abstract: The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between predictive and prognostic biomarkers can be challenging due to the overlap between the two. A ... ...

    Abstract The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between predictive and prognostic biomarkers can be challenging due to the overlap between the two. A prognostic biomarker predicts the future outcome of cancer, regardless of treatment, and a predictive biomarker predicts the effectiveness of a therapeutic intervention. Misclassifying a prognostic biomarker as predictive (or vice versa) can have serious financial and personal consequences for patients. To address this issue, various statistical and machine learning approaches have been developed. The aim of this study is to present an in-depth analysis of recent advancements, trends, challenges, and future prospects in biomarker identification. A systematic search was conducted using PubMed to identify relevant studies published between 2017 and 2023. The selected studies were analyzed to better understand the concept of biomarker identification, evaluate machine learning methods, assess the level of research activity, and highlight the application of these methods in cancer research and treatment. Furthermore, existing obstacles and concerns are discussed to identify prospective research areas. We believe that this review will serve as a valuable resource for researchers, providing insights into the methods and approaches used in biomarker discovery and identifying future research opportunities.
    MeSH term(s) Humans ; Biomarkers, Tumor ; Prognosis ; Prospective Studies ; Biomarkers/analysis ; Precision Medicine ; Machine Learning ; Neoplasms/diagnosis
    Chemical Substances Biomarkers, Tumor ; Biomarkers
    Language English
    Publishing date 2023-04-24
    Publishing country Switzerland
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24097781
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Tumor Evolution: A Problem of Histocompatibility

    Vokes, Natalie I / Van Allen, Eliezer M

    Cell. 2017 Nov. 30, v. 171, no. 6

    2017  

    Abstract: In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cell survival. ...

    Abstract In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cell survival.
    Keywords HLA antigens ; antigen presentation ; cell viability ; disease course ; immunogenicity ; neoplasm cells ; neoplasms
    Language English
    Dates of publication 2017-1130
    Size p. 1252-1253.
    Publishing place Elsevier Inc.
    Document type Article
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2017.11.012
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 75/702: Show issues
    Z 93: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.

    Nishino, Mizuki / Lu, Junwei / Hino, Takuya / Vokes, Natalie I / Jänne, Pasi A / Hatabu, Hiroto / Johnson, Bruce E

    Journal of thoracic imaging

    2021  Volume 38, Issue 2, Page(s) 82–87

    Abstract: Purpose: In patients with advanced non-small cell lung cancer (NSCLC) and oncogenic driver mutations treated with effective targeted therapy, a characteristic pattern of tumor volume dynamics with an initial regression, nadir, and subsequent regrowth is ...

    Abstract Purpose: In patients with advanced non-small cell lung cancer (NSCLC) and oncogenic driver mutations treated with effective targeted therapy, a characteristic pattern of tumor volume dynamics with an initial regression, nadir, and subsequent regrowth is observed on serial computed tomography (CT) scans. We developed and validated a linear model to predict the tumor volume nadir in EGFR -mutant advanced NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKI).
    Materials and methods: Patients with EGFR -mutant advanced NSCLC treated with EGFR-TKI as their first EGFR-directed therapy were studied for CT tumor volume kinetics during therapy, using a previously validated CT tumor measurement technique. A linear regression model was built to predict tumor volume nadir in a training cohort of 34 patients, and then was validated in an independent cohort of 84 patients.
    Results: The linear model for tumor nadir prediction was obtained in the training cohort of 34 patients, which utilizes the baseline tumor volume before initiating therapy (V 0 ) to predict the volume decrease (mm 3 ) when the nadir volume (V p ) was reached: V 0 -V p =0.717×V 0 -1347 ( P =2×10 -16

    R2 =0.916). The model was tested in the validation cohort, resulting in the R2 value of 0.953, indicating that the prediction model generalizes well to another cohort of EGFR -mutant patients treated with EGFR-TKI. Clinical variables were not significant predictors of tumor volume nadir.
    Conclusion: The linear model was built to predict the tumor volume nadir in EGFR -mutant advanced NSCLC patients treated with EGFR-TKIs, which provide an important metrics in treatment monitoring and therapeutic decisions at nadir such as additional local abrasive therapy.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Tyrosine Kinase Inhibitors ; Tumor Burden ; Protein Kinase Inhibitors/therapeutic use ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Mutation
    Chemical Substances Tyrosine Kinase Inhibitors ; Protein Kinase Inhibitors ; ErbB Receptors (EC 2.7.10.1) ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2021-09-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632900-7
    ISSN 1536-0237 ; 0883-5993
    ISSN (online) 1536-0237
    ISSN 0883-5993
    DOI 10.1097/RTI.0000000000000615
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2187: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top